Laregab-AT Tablet is a combination medication containing Gabapentin 300 mg and Amitriptyline 10 mg, indicated for the management of neuropathic pain and certain types of chronic pain disorders. Gabapentin, an anticonvulsant, modulates neuronal excitability by binding to the alpha-2-delta subunit of voltage-gated calcium channels, thereby reducing neurotransmitter release and alleviating neuropathic pain. Amitriptyline, a tricyclic antidepressant, exerts analgesic effects through inhibition of norepinephrine and serotonin reuptake, enhancing descending inhibitory pain pathways. This synergistic formulation is beneficial in patients who require multimodal pain relief, particularly in conditions such as diabetic neuropathy, postherpetic neuralgia, and fibromyalgia. Laregab-AT should be administered as prescribed by a healthcare professional, with dosage adjustments based on therapeutic response and tolerability. Common adverse effects may include dizziness, drowsiness, dry mouth, and gastrointestinal disturbances. Caution is advised in patients with a history of cardiac disorders, glaucoma, or those taking other central nervous system depressants. Laregab-AT is contraindicated in individuals with hypersensitivity to either component. Regular monitoring and adherence to prescribed dosage are essential to optimize efficacy and minimize potential side effects. This combination therapy offers a comprehensive approach to neuropathic pain management by targeting multiple pain pathways.